SELP and pulmonary arterial hypertension: Additionally, in patients with connective tissue diseases and PAH, a 3-month scheme of bosentan could ameliorate several biomarkers of endothelial function such as NO and sCD40 L and clinical status; interestingly, responders to the treatment demonstrated a decrease in P-selectin levels [266].